The Oncology Institute, Inc. reported Q4 and FY 2025 financial results, highlighting a 41.6% revenue increase to $142.0 million in Q4 and positive Adjusted EBITDA of $147 thousand. The Company also issued FY 2026 guidance, projecting revenue of $630 to $650 million and positive full-year Adjusted EBITDA.
Key takeaways
Q4 2025 consolidated revenue increased 41.6% to $142.0 million compared to the quarter ended December 31, 2024.
Q4 2025 Adjusted EBITDA was $147 thousand, compared to $(7.8) million in the prior year quarter.
Full year 2025 consolidated revenue increased 27.8% to $502.7 million.
The Company initiated 9 new capitated contracts in 2025, adding approximately 260,000 lives under management.
FY 2026 guidance projects revenue of $630 to $650 million and Adjusted EBITDA of $0 to $9 million.
Cash and cash equivalents totaled $33.6 million as of December 31, 2025.